Discover the Latest Follicular Lymphoma Treatments!

Follicular Lymphoma Treatments

Massive Bio’s advanced Artificial Intelligence system will match and suggest a range of potential follicular lymphoma treatments tailored to your unique medical situation. Our Patient Relations Coordinators will evaluate your submission and promptly reach out to discuss your eligibility for our follicular lymphoma clinical trials.

What is Follicular Lymphoma?

Diagnosis:

Before considering clinical trials, it is important to understand the disease. Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma (NHL), accounting for 30% of all lymphomas. It originates in the B-lymphocytes, a type of white blood cell. Slow growth characterizes it, and it can often be asymptomatic for a long period.

Which are the most common Follicular Lymphoma symptoms?

The symptoms of Follicular Lymphoma you should be aware of are the following:

• Painless swelling of lymph nodes in the neck, armpit, or groin.
• Fatigue: Persistent tiredness or weakness.
• Fever: Unexplained and recurring fevers considered a B symptom.
• Night Sweats: Profuse sweating during the night, considered a B symptom.
• Weight Loss: Unintentional loss of more than 10% of body weight over six months, considered a B symptom.
• Abdominal Pain or Fullness: Often due to an enlarged spleen or lymph nodes.

B symptoms refer to systemic symptoms of fever, night sweats, and weight loss that can indicate a more aggressive disease course and are used in staging and prognosis of lymphomas.

Grades of Follicular Lymphoma:

Follicular lymphoma cancer is graded based on the number of large cells, called centroblasts, observed under a microscope:

• Grade 1-2: Few centroblasts; generally slower growing.
• Grade 3A: More centroblasts but still shows a follicular pattern.
• Grade 3B: High number of centroblasts, usually considered more aggressive and may be treated like diffuse large B-cell lymphoma (DLBCL).

Grade 3B, mostly known as diffuse large B-cell lymphoma (DLBCL) or undergoing transformation to a high-grade lymphoma, is typically excluded from clinical trials of Follicular Lymphoma and instead considered for DLBCL trials. This ensures appropriate treatment strategies and trial relevance for different lymphoma behaviors.

Staging Follicular Lymphoma

• Stage I Follicular Lymphoma: Involvement of a single lymph node region or a single extra lymphatic organ.
• Stage II Follicular Lymphoma: Involvement of two or more lymph node regions on the same side of the diaphragm or localized involvement of an extra lymphatic organ and its regional lymph nodes.
• Stage II Bulky: Stage II with one or more lymph nodes measuring 6 cm or larger.
• Stage III Follicular Lymphoma: Involvement of lymph node regions on both sides of the diaphragm, which may also be accompanied by localized involvement of an extra lymphatic organ.
• Stage IV Follicular Lymphoma: Disseminated involvement of one or more extra lymphatic organs with or without lymph node involvement.

Treated vs. Untreated Follicular Lymphoma

• Untreated Follicular Lymphoma: Often managed with a “watch and wait” approach, especially if asymptomatic or slow-growing.
• Treated Follicular Lymphoma: Therapy may include chemotherapy, targeted therapy, radiation, and immunotherapy. The treatment approach depends on the stage, grade, and symptoms.

We have an incredible opportunity for you to access new therapies that can revolutionize your journey with Follicular Lymphoma, a type of non-Hodgkin’s lymphoma. Clinical trials are open to individuals with a Follicular Lymphoma diagnosis, regardless of their treatment status, providing an opportunity for both newly diagnosed patients who haven’t started treatment and those who have undergone previous therapies.

What are the treatment options for
Follicular Lymphoma?

Chemotherapy: Drugs that kill or slow the growth of rapidly dividing cells. Effective for broad cancer cell destruction, often used as a standard initial treatment.

Targeted Therapy: Drugs designed to target specific molecules involved in cancer cell growth and survival.

• Anti-CD20: Antibodies that target the CD20 antigen on B-cells, leading to their destruction. Used in nearly all treatment regimens for follicular lymphoma.
• Immunomodulatory Drugs: Agents that modulate the immune system to enhance anti-tumor effects.
• BTK Inhibitors: Block Bruton’s tyrosine kinase, disrupting B-cell receptor signaling and inducing cancer cell death.
• EZH2 Inhibitors: Inhibit EZH2, an enzyme promoting cancer cell proliferation in cases with specific mutations.

Radiation Therapy: Uses high-energy rays to kill cancer cells, typically used for localized disease.

Immunotherapy: Enhances the body’s immune response to cancer.

• CAR T-cell Therapy: Genetically modified T-cells designed to attack cancer cells.
• Stem Cell Transplant replaces sick bone marrow with healthy stem cells, often used for relapsed or refractory Follicular Lymphoma.

Clinical trials aim to develop new drugs, treatment strategies, and combinations for follicular lymphoma to enhance patient outcomes, improve quality of life, and discover innovative therapies.

Genetic Testing on Follicular Lymphoma

Immunohistochemistry (IHC): is a laboratory technique used to detect specific antigens (proteins) in cells within tissue sections using antibodies. The following biomarkers are crucial in the treatment of follicular lymphoma (FL) as they help in diagnosing the disease, predicting treatment response, and personalizing therapy:

• CD20: A protein expressed on the surface of B-cells; almost universally present in FL.
• CD10: A marker of germinal center B-cells, expressed in approximately 60-70% of FL cases.
• BCL2: Overexpressed due to t(14;18) translocation, present in about 85% of FL cases.
• BCL6: A marker of germinal center B-cells, involved in cell differentiation and proliferation.

Next-Generation Sequencing (NGS): Is a method used to analyze genetic mutations, providing detailed information about genetic alterations. The most common biomarkers are:

• BCL2: Mutation and translocation t(14;18) found in approximately 85% of cases.
• EZH2: Mutations found in around 20% of FL cases, associated with better prognosis.
• CREBBP: Mutations present in about 60% of FL cases.

Fluorescence In Situ Hybridization (FISH): This lab technique uses glowing probes to highlight specific parts of DNA on chromosomes. It is especially important in follicular lymphoma because it can detect key genetic changes, like the t(14;18) translocation, which causes an overproduction of the BCL2 protein and helps cancer cells survive.

The Role of Follicular Lymphoma
Clinical Trials

Innovative Therapy: Our cutting-edge therapy brings together the latest advancements in medical science and technology to target your follicular B-cell lymphoma with precision and effectiveness.

Personalized Match: We understand that every patient is unique, and that’s why we focus on matching you with a treatment plan that aligns with your specific requirements and medical history, whether you’re dealing with indolent follicular lymphoma, untreated follicular lymphoma, refractory follicular lymphoma, or recurrent follicular lymphoma.

Expert Guidance: Throughout your journey, even with low-grade lymphoma, our experienced team of medical professionals will be by your side, providing guidance, support, and answering any questions you may have.

By signing up for our matching program, you’re taking an active role in exploring new possibilities and gaining access to innovative therapy that can potentially transform your life. Don’t miss out on this opportunity to enhance your Follicular Lymphoma treatment.

Join us today and let’s embark on this extraordinary path towards improved health together!